Videra Health Launches “Check on Mom,” the First Free AI-Powered Postpartum Depression Screener

Videra Health Logo

New initiative empowers moms with a confidential, stigma-free video screener for postpartum depression, powered by conversational AI

Orem, UT, September 23, 2025 – Videra Health, a leading AI platform for behavioral health providers, today announced the launch of Check on Mom, the first free, confidential AI-powered postpartum depression screener. The self-assessment tool empowers mothers to complete a private, video-based check-in using conversational AI that captures both verbal and non-verbal signs of postpartum depression (PPD) and generates results they can share with a provider.

Unlike traditional written screeners, Check on Mom uses video and AI language models trained specifically for healthcare to analyze both spoken words and non-verbal cues. This dual-layer approach provides deeper insights into maternal mental health, making it easier to distinguish between common “baby blues” and postpartum depression.

“Check on Mom is not just a digital tool, it is a public health resource,” said Loren Larsen, co-founder and CEO of Videra Health. “By showing what is possible with AI-powered video screeners, we are opening new opportunities for earlier detection and better outcomes, not just in maternal health but across conditions where timely screening can make a real difference for patients and providers.”

How Check on Mom Works:

  • Free and confidential: No insurance, no cost.
  • Fast and convenient: Completed on almost any device, at any time, in less than three minutes.
  • Video-based and shame-free: Instead of static surveys, moms can speak openly and naturally about how they feel, and results are theirs to share
  • Clinically validated insights: Downloadable results can be shared with OBs, midwives, or primary care providers to guide next steps.

One in eight mothers experience postpartum depression, yet most go undiagnosed or untreated because screenings are inconsistent, stigma persists, and support often arrives too late. With Check on Mom, any mother can complete a short, video-based screener in just a few minutes and access secure results immediately without waiting for a six-week appointment or navigating health system barriers.

Check on Mom is more than a consumer resource. It is a proof point for how AI can transform condition-specific screening at scale. By applying conversational AI and video analysis, Videra Health is creating earlier pathways to care for conditions that are too often overlooked.

In addition to proprietary AI models already used to screen for depression, anxiety, trauma, and other conditions, the company most recently released TDScreen, the first AI-powered screener for tardive dyskinesia. These tools show how AI screeners can:

  • Expand access to early detection in underserved populations.
  • Deliver patient-centered insights that improve diagnosis and treatment.
  • Provide adaptable, condition-specific screening models that can be applied across therapeutic areas.

Across healthcare from patients and providers to pharma leaders, Check on Mom demonstrates how technology can expand access to postpartum depression screening, improve early detection, and support better patient outcomes. Videra is working to normalize maternal mental health conversations and demonstrate a new model for patient-first innovation.

Check on Mom is available free of charge for any mom wanting to screen for postpartum depression. Visit www.checkonmom.ai to learn more.

About Videra Health™

Videra Health is a leading AI platform for behavioral health providers and proactively identifies, triages and monitors at-risk patients using linguistic, audio and video analysis. The FDA-registered digital platform transforms how doctors and healthcare systems interact and track a patient’s journey, illuminating the hidden depths of patient behavior and outcomes. Videra Health connects providers and patients anytime, anywhere, between visits and post-discharge via written and video assessments that translate into actionable quantitative and qualitative patient data. The platform streamlines diagnoses, enhances care accessibility, optimizes workflows and drives down costs for providers and healthcare systems.

Videra Health Launches TDScreen, a First-of-Its-Kind Video-based, AI-powered Tool to Assess Tardive Dyskinesia Symptoms

Videra Health Logo

New study published in the Journal of Clinical Psychiatry reveals AI enables efficient, accurate and scalable detection of TD, representing a significant advancement in meeting the standard of care for TD screening

Orem, UT, June 3, 2025 – Videra Health, a leading AI platform for behavioral health providers, has announced the launch of TDScreen, the first-ever automated, video-based AI solution on the market to screen for Tardive Dyskinesia (TD) symptoms. TD is a chronic, involuntary movement disorder that can develop as a side effect of long-term use of certain medications, particularly antipsychotic drugs. While TDScreen isn’t intended as a standalone diagnostic tool, it represents a significant advancement in meeting the standard of care for TD screening.

TD presents unique screening challenges even for experienced clinicians and remains underdiagnosed. TD affects up to 2.6 million Americans, and up to 7 million Americans taking antipsychotic medications could develop TD symptoms. With its involuntary movements often mistaken for nervousness, aging, or other conditions, the gap in recognition represents not just a clinical challenge, but a deeply human one that affects quality of life and treatment outcomes. A paper published Wednesday in The Journal of Clinical Psychiatry, led by Principal Investigator Dr. Anthony Sterns and members of the iRxReminder and Videra Health teams, reveals that video-based AI enables efficient, accurate, and scalable detection of TD. This application has the potential to significantly improve early diagnosis and patient outcomes, especially in remote care settings where resources are scarcest. Videra Health’s TDScreen algorithm was built using the data from multiple studies, which was supported in part by the National Institute of Mental Health, and represents a significant leap forward in integrating artificial intelligence into psychiatric care, particularly in the era of telemedicine.

“Videra Health is thrilled to be able to launch a first-of-its-kind innovative solution to screen for TD symptoms, effectively,” said Loren Larsen, CEO of Videra Health. “TDScreen and our broader AI platform aren’t about replacing clinician judgment—they’re about enhancing it. By automating routine screenings, we free healthcare providers to focus on what matters most: the human connections and complex decision-making that drive quality care.” Larsen added, “We are grateful for the multiple academic and research partners who have contributed their time and expertise to these studies.”

“Early detection of TD is critical to mitigating its debilitating effects,” said Dr. Anthony A. Sterns, Ph.D., lead researcher on the project and CEO at iRxReminder. “Our AI-driven approach not only matches but exceeds human expert performance, offering a scalable solution to a major unmet clinical need,” added Dr. Joel W. Hughes, Ph.D., collaborator from Kent State University.

“As a physician who both treats –and lives with– tardive dyskinesia, this research marks a turning point for millions of patients who have been forced to wonder if the movement disorder they suffer from could be treatable,” says Owen S, Muir, M.D., CMO of iRxReminder, CMO and co-founder of Radial Health, and co-author of the publication.  “Now, physicians have a simple, evidence-based AI-guided tool to support their clinical decision making.”

TDScreen was validated across three clinical studies involving more than 350 participants on antipsychotic medications. The innovative AI tool developed by Videra Health utilizes advanced video analysis and a vision transformer machine learning architecture to detect TD with unprecedented accuracy. TDScreen demonstrates a Cohen’s Kappa of 0.61—a number indicating the algorithm is outperforming even calibrated human raters. The algorithm achieved an area under the receiver-operating-characteristic curve (AUC) of 0.89, surpassing the sensitivity and specificity of trained human raters using the standard Abnormal Involuntary Movement Scale (AIMS).

These numbers represent more than just statistical achievements—they translate to real-world benefits:

  • Consistency: Unlike human raters whose assessments may vary, AI provides the same evaluation standards every time
  • Accessibility: Patients can complete assessments from home on their own devices
  • Efficiency: Providers save valuable clinical time while increasing screening frequency
  • Earlier detection: Subtle symptoms can be identified before they become pronounced

Continuous monitoring: Regular assessments track symptom progression or improvement

With TDScreen, patients on antipsychotics can easily complete video-based screenings in-office or remotely, and enable providers to monitor or modify their treatment plans. The TDScreen tool is based on the Abnormal Involuntary Movement Scale (AIMS), a comprehensive clinician-rated scale designed to specifically evaluate involuntary movements. Employing advanced AI video technology, TDScreen efficiently assesses and quantifies the risk of TD in less than 5 minutes. The resulting score generated by this assessment can aid in clinical decision-making and management strategies.

TDscreen is available free of charge for any provider or patient wanting to screen for TD. Visit tdscreen.ai to learn more.

About Videra Health™

Videra Health is a leading AI platform for behavioral health providers and proactively identifies, triages and monitors at-risk patients using linguistic, audio and video analysis. The FDA-registered digital platform transforms how doctors and healthcare systems interact and track a patient’s journey, illuminating the hidden depths of patient behavior and outcomes. Videra Health connects providers and patients anytime, anywhere, between visits and post-discharge via written and video assessments that translate into actionable quantitative and qualitative patient data. The platform streamlines diagnoses, enhances care accessibility, optimizes workflows and drives down costs for providers and healthcare systems. 

For more information, visit www.viderahealth.com.

About iRxReminder
iRxReminder specializes in digital health solutions aimed at enhancing medication adherence and mental health management through cutting-edge technology applications and innovative behavioral science solutions.

For more information, visit www.irxreminder.com.